review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Yongwon Choi | |
Matthew C Walsh | |||
P2860 | cites work | Emerging Functions of RANKL in Lymphoid Tissues | Q21131222 |
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis | Q24297505 | ||
Distinct molecular mechanism for initiating TRAF6 signalling | Q24302174 | ||
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation | Q24315189 | ||
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 | ||
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 | Q24537518 | ||
RANK is essential for osteoclast and lymph node development | Q24598872 | ||
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
Targeting RANKL in metastasis | Q26849690 | ||
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif | Q28138697 | ||
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene | Q59092154 | ||
Pathogenesis of osteoporosis | Q73280016 | ||
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines | Q74269794 | ||
Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis | Q77435071 | ||
Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF) | Q77630526 | ||
Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells | Q77630549 | ||
Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals | Q77704341 | ||
Self-assembled RANK induces osteoclastogenesis ligand-independently. | Q40360377 | ||
MLO-Y4 osteocyte-like cells support osteoclast formation and activation | Q40692837 | ||
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells | Q40927574 | ||
OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. | Q40991620 | ||
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines | Q41000781 | ||
TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption | Q41027241 | ||
Osteoprotection by semaphorin 3A. | Q41791623 | ||
Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured "miniguts". | Q42321791 | ||
Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis | Q42795870 | ||
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function | Q42811314 | ||
Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling | Q43648531 | ||
Bifurcation of osteoclasts and dendritic cells from common progenitors | Q43757343 | ||
p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function | Q44072080 | ||
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis | Q44688981 | ||
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis | Q47884508 | ||
Osteoprotegerin deficiency and juvenile Paget's disease | Q48292818 | ||
TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. | Q50335956 | ||
Progesterone/RANKL is a major regulatory axis in the human breast. | Q51042996 | ||
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 | ||
Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. | Q51997176 | ||
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. | Q52172979 | ||
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. | Q52532345 | ||
LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. | Q53955124 | ||
TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells | Q56975249 | ||
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells | Q57184743 | ||
NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 | Q57675122 | ||
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β | Q57675150 | ||
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation | Q57675158 | ||
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms | Q58326878 | ||
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
Matrix-embedded cells control osteoclast formation | Q28247746 | ||
Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase | Q28278061 | ||
The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily | Q28291317 | ||
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin | Q28294196 | ||
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
Osteoimmunology: interplay between the immune system and bone metabolism | Q28303107 | ||
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | Q28508430 | ||
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium | Q29397534 | ||
Osteoclast differentiation and activation | Q29547556 | ||
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism | Q30168144 | ||
Dynamic visualization of RANKL and Th17-mediated osteoclast function. | Q30533914 | ||
Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance | Q33569842 | ||
Cell biology of the osteoclast | Q33700885 | ||
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction | Q33886695 | ||
A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. | Q33951432 | ||
FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner | Q34014506 | ||
Strength of TRAF6 signalling determines osteoclastogenesis | Q34166675 | ||
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2 | Q34302372 | ||
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit | Q34750367 | ||
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
Ubiquitination in signaling to and activation of IKK. | Q37995681 | ||
New developments in osteoimmunology | Q38052462 | ||
Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo | Q38114066 | ||
Osteoprotegerin: multiple partners for multiple functions | Q38119335 | ||
Regulations of gene expression in medullary thymic epithelial cells required for preventing the onset of autoimmune diseases | Q38132390 | ||
Management of bone disease in multiple myeloma | Q38179039 | ||
RANKL/RANK - from bone physiology to breast cancer | Q38184201 | ||
Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. | Q38311660 | ||
Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator | Q38363724 | ||
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus | Q39197051 | ||
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
Biology of the TRANCE axis | Q35145622 | ||
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine. | Q35235833 | ||
Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling | Q35598825 | ||
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice | Q35607627 | ||
RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations | Q35837418 | ||
RGS10-null mutation impairs osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation | Q35893658 | ||
Rank signaling links the development of invariant γδ T cell progenitors and Aire(+) medullary epithelium | Q36011240 | ||
Jagged1 and Notch1 help edit M cell patterning in Peyer's patch follicle epithelium | Q36028169 | ||
Mechanistic insight into osteoclast differentiation in osteoimmunology | Q36073894 | ||
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss | Q36216058 | ||
TRAF family member-associated NF-κB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation | Q36217430 | ||
Osteocyte RANKL: new insights into the control of bone remodeling | Q36253514 | ||
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE | Q36368551 | ||
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 | ||
TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo | Q36375923 | ||
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice | Q36512214 | ||
The thymic medulla is required for Foxp3+ regulatory but not conventional CD4+ thymocyte development | Q36750060 | ||
Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines | Q36889722 | ||
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium | Q36940409 | ||
DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. | Q36977266 | ||
The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells | Q36991688 | ||
Osteoporosis and inflammation | Q37073877 | ||
The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo | Q37114842 | ||
Advances in the regulation of osteoclasts and osteoclast functions | Q37177840 | ||
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis | Q37302910 | ||
NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism | Q37363042 | ||
Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation | Q37410560 | ||
TRAF3 enforces the requirement for T cell cross-talk in thymic medullary epithelial development | Q37421214 | ||
The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase | Q37647341 | ||
Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals | Q37825125 | ||
Rank/Rankl/opg: literature review | Q37960379 | ||
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 511 | |
P577 | publication date | 2014-10-20 | |
P1433 | published in | Frontiers in Immunology | Q27723748 |
P1476 | title | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | |
P478 | volume | 5 |
Q49816359 | A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5. |
Q43239608 | A bone to pick with Fc gamma receptors |
Q35659971 | Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors |
Q51481227 | Anabolic Effect of Insulin Therapy on the Bone: Osteoprotegerin and Osteocalcin Up-Regulation in Streptozotocin-Induced Diabetic Rats. |
Q47232189 | Anti-inflammatory and antiresorptive effects of Calendula officinalis on inflammatory bone loss in rats. |
Q39367844 | Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts. |
Q64983997 | Association of OPG gene polymorphisms with the risk of knee osteoarthritis among Chinese people. |
Q94594156 | Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis |
Q47194100 | Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss |
Q38748557 | Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases |
Q93079405 | Bone Diseases in Patients with Chronic Liver Disease |
Q42738566 | Burn Injury Has Skeletal Site-Specific Effects on Bone Integrity and Markers of Bone Remodeling |
Q38679996 | CCL11, a novel mediator of inflammatory bone resorption |
Q49918706 | CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance |
Q38725092 | Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis |
Q92888941 | Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density |
Q92636699 | Clinical Impact of RANK Signalling in Ovarian Cancer |
Q90468465 | Combined Hydroxyapatite Scaffold and Stem Cell from Human Exfoliated Deciduous Teeth Modulating Alveolar Bone Regeneration via Regulating Receptor Activator of Nuclear Factor-Κb and Osteoprotegerin System |
Q37246486 | Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case. |
Q34545263 | Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. |
Q50797973 | Development of a High-Throughput Screening Strategy for Upregulators of the OPG/RANKL Ratio with the Potential for Antiosteoporosis Effects. |
Q48232446 | Development of intestinal M cells and follicle-associated epithelium is regulated by TRAF6-mediated NF-κB signaling. |
Q91921619 | Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption? |
Q50437421 | Dual Role of Cyanidin-3-glucoside on the Differentiation of Bone Cells. |
Q37640969 | Effect of 15-Deoxy-Δ12,14-prostaglandin J2Nanocapsules on Inflammation and Bone Regeneration in a Rat Bone Defect Model |
Q36245404 | Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. |
Q47335443 | Effects of Osteogenic-Conditioned Medium from Human Periosteum-Derived Cells on Osteoclast Differentiation |
Q39421442 | Effects of low-frequency ultrasound treatment of titanium surface roughness on osteoblast phenotype and maturation. |
Q38759519 | Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway. |
Q39025251 | Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial. |
Q96343329 | Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis |
Q90694726 | Glucocorticoids Influencing Wnt/β-Catenin Pathway; Multiple Sites, Heterogeneous Effects |
Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
Q90290403 | Hexane Fraction of Turbo brunneus Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss |
Q54094991 | High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice. |
Q92589579 | Highlight Article: Identifying human and murine M cells in vitro |
Q93093562 | How, When, and Where Do Human β-Cells Regenerate? |
Q92494321 | Human Enriched Serum Following Hydrolysed Collagen Absorption Modulates Bone Cell Activity: from Bedside to Bench and Vice Versa |
Q91928122 | Human gingival tissue-derived MSC suppress osteoclastogenesis and bone erosion via CD39-adenosine signal pathway in autoimmune arthritis |
Q48261321 | ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo |
Q92981853 | Identification of key biomarkers and immune infiltration in the synovial tissue of osteoarthritis by bioinformatics analysis |
Q64118198 | Imaging the Bone-Immune Cell Interaction in Bone Destruction |
Q37701076 | Immune mediators in the tumor microenvironment of prostate cancer |
Q36766801 | Immunology of Osteoporosis: A Mini-Review |
Q64058797 | Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL) |
Q92305864 | Impact of Periprosthetic Fibroblast-Like Cells on Osteoclastogenesis in Co-Culture with Peripheral Blood Mononuclear Cells Varies Depending on Culture System |
Q48297258 | Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis. |
Q37288057 | Increased receptor activator of nuclear factor κβ ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitro |
Q90450587 | Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression |
Q89167818 | Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity |
Q92406823 | Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review |
Q54967737 | Interleukin-33 Receptor (ST2) Deficiency Improves the Outcome of Staphylococcus aureus-Induced Septic Arthritis. |
Q86706212 | Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes |
Q57808156 | Intraarticular injection of dexamethasone promotes bone erosion in collagen-induced arthritis in mice through up-regulation of RANKL expression |
Q51283972 | Inverse Association Between Serum Osteoprotegerin and Bone Mineral Density in Renal Transplant Recipients. |
Q50271314 | Jagged1 inhibits osteoprotegerin expression by human periodontal ligament cells |
Q47146850 | KLF2 in Regulation of NF-κB-Mediated Immune Cell Function and Inflammation |
Q97643389 | Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin |
Q36384666 | Low-level laser therapy (780 nm) combined with collagen sponge scaffold promotes repair of rat cranial critical-size defects and increases TGF-β, FGF-2, OPG/RANK and osteocalcin expression |
Q38615856 | Macrophage Polarization and Bone Formation: A review. |
Q41988197 | Managing sarcoma: where have we come from and where are we going? |
Q63762081 | Mandibular Bone Loss after Masticatory Muscles Intervention with Botulinum Toxin: An Approach from Basic Research to Clinical Findings |
Q42068905 | Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2. |
Q58582775 | Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups |
Q42261478 | Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis |
Q42262105 | Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis |
Q58607146 | Metformin Hydrochloride-Loaded PLGA Nanoparticle in Periodontal Disease Experimental Model Using Diabetic Rats |
Q89094526 | Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy |
Q48370440 | Molecular insights into the mechanisms of M-cell differentiation and transcytosis in the mucosa-associated lymphoid tissues |
Q92349783 | Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review |
Q37733733 | Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. |
Q61806935 | Moxibustion of Zusanli (ST36) and Shenshu (BL23) Alleviates Cartilage Degradation through RANKL/OPG Signaling in a Rabbit Model of Rheumatoid Arthritis |
Q39014215 | Murine Rankl-/- Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector |
Q36810697 | Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles |
Q35684515 | Nanosecond pulsed electric field inhibits proliferation and induces apoptosis in human osteosarcoma |
Q89345508 | Neutrophils: Friend, foe, or contextual ally in myocardial healing |
Q28067712 | Novel biological markers of bone: from bone metabolism to bone physiology |
Q38951158 | Novel factors modulating human β-cell proliferation |
Q38952629 | Of skin and bone: did Langerhans cells and osteoclasts evolve from a common ancestor? |
Q55338724 | Osteoclast-Derived Extracellular Vesicles: Novel Regulators of Osteoclastogenesis and Osteoclast-Osteoblasts Communication in Bone Remodeling. |
Q52655586 | Osteogenesis imperfecta and therapeutics. |
Q96305136 | Osteoimmunomodulatory effects of biomaterial modification strategies on macrophage polarization and bone regeneration |
Q42276289 | Osteopontin inhibits osteoblast responsiveness through the down-regulation of focal adhesion kinase mediated by the induction of low-molecular weight protein tyrosine phosphatase. |
Q88336719 | Osteoprotegerin deficiency causes morphological and quantitative damage in epithelial rests of Malassez |
Q92609860 | Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity |
Q41513671 | Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction |
Q36388215 | Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk |
Q58707909 | Polyphenols (S3) Isolated from Cone Scales of Pinus koraiensis Alleviate Decreased Bone Formation in Rat under Simulated Microgravity |
Q38833288 | Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression |
Q47834751 | Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand. |
Q48277954 | Posttranscriptional Interaction Between miR-450a-5p and miR-28-5p and STAT1 mRNA Triggers Osteoblastic Differentiation of Human Mesenchymal Stem Cells |
Q55410884 | Prevention and Treatment of Osteoporosis Using Chinese Medicinal Plants: Special Emphasis on Mechanisms of Immune Modulation. |
Q42376243 | Protective effect of Rhus verniciflua Stokes extract in an experimental model of post-menopausal osteoporosis |
Q47420424 | Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling |
Q38691526 | RANK as a therapeutic target in cancer. |
Q64939796 | RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. |
Q26747442 | RANK-RANKL signalling in cancer |
Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
Q50215136 | Recent advances in osteoclast biology. |
Q92477601 | Receptor activator of the NFκB ligand system protects renal function during experimental renal ischemia-reperfusion in mice |
Q36310371 | Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO) |
Q55226585 | Regulation of Osteoclast Differentiation by Cytokine Networks. |
Q43169774 | Regulation of Tissue Responses: The TWEAK/Fn14 Pathway and Other TNF/TNFR Superfamily Members That Activate Non-Canonical NFκB Signaling |
Q93165466 | Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy |
Q52718664 | Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity. |
Q90884836 | Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps |
Q36285195 | Role of odanacatib in reducing bone loss due to endodontic disease: An overview |
Q92738306 | Role of osteoprotegerin in the regulation of dental epithelial‑mesenchymal signaling during tooth development |
Q37479739 | Senescence: novel insight into DLX3 mutations leading to enhanced bone formation in Tricho-Dento-Osseous syndrome. |
Q48033151 | Serum CX3CL1/fractalkine concentrations are positively associated with disease severity in postmenopausal osteoporotic patients |
Q97643643 | Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone |
Q35658848 | Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor. |
Q92402534 | Sox8 is essential for M cell maturation to accelerate IgA response at the early stage after weaning in mice |
Q36029297 | Sphingosine-1-Phosphate Receptor 2 Regulates Proinflammatory Cytokine Production and Osteoclastogenesis. |
Q90415487 | Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL /RANK and osteoprotegerin (OPG) system |
Q33838494 | Suppression of Osteoclastogenesis by Melatonin: A Melatonin Receptor-Independent Action |
Q39287117 | TNF and Bone Remodeling |
Q38733018 | TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of Ovariectomy-Induced Bone Loss by a Novel Prenylflavonoid. |
Q57168746 | The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease |
Q57790452 | The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases |
Q26773017 | The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis |
Q98177574 | The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases |
Q50531937 | The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders. |
Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
Q64274656 | The Role of Osteoprotegerin and Its Ligands in Vascular Function |
Q88862150 | The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies |
Q88954027 | The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells |
Q91105567 | The cytokine network involved in the host immune response to periodontitis |
Q38682669 | The effects of chitosan oligosaccharides on OPG and RANKL expression in a rat osteoarthritis model |
Q59801718 | The impact of immune response on endochondral bone regeneration |
Q100512479 | The third case of TNFRSF11A-associated dysosteosclerosis with a mutation producing elongating proteins |
Q35284151 | The unsolved case of "bone-impairing analgesics": the endocrine effects of opioids on bone metabolism |
Q91940103 | Therapeutic effect of low-intensity pulsed ultrasound on temporomandibular joint injury induced by chronic sleep deprivation in rats |
Q36054527 | Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. |
Q90176917 | Transcript Analysis Reveals a Hypoxic Inflammatory Environment in Human Chronic Otitis Media With Effusion |
Q98303052 | Transcriptome sequencing supports a conservation of macrophage polarization in fish |
Q38414568 | Update on genetics and pathogenesis of autoinflammatory diseases: the last 2 years |
Q50093296 | Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity |
Q91393746 | Western-type diet differentially modulates osteoblast, osteoclast, and lipoblast differentiation and activation in a background of APOE deficiency |
Q95402467 | [Effect of MT01/PEN complexes on the expression of osteoprotegerin and receptor activator of nuclear factor κB ligand in human osteoblast-like cell line MG63] |
Q40667963 | hMSC-Derived VEGF Release Triggers the Chemoattraction of Alveolar Osteoblasts |
Q44536102 | p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model. |
Q36506638 | α1B-Adrenergic receptor signaling controls circadian expression of Tnfrsf11b by regulating clock genes in osteoblasts |